CC BY-NC-ND 4.0 · Semin Thromb Hemost 2014; 40(02): 163-171
DOI: 10.1055/s-0033-1364185
In Focus Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Recent Guidelines and Recommendations for Laboratory Detection of Lupus Anticoagulants

Gary W. Moore
1   Department of Haemostasis and Thrombosis, GSTS Pathology, Guy's & St. Thomas' NHS Foundation Hospitals Trust, London, England
› Author Affiliations
Further Information

Publication History

Publication Date:
05 February 2014 (online)

Abstract

The International Society on Haemostasis and Thrombosis (ISTH) and the British Committee for Standards in Haematology (BCSH) have recently updated their lupus anticoagulant (LA) detection guidelines. The Clinical and Laboratory Standards Institute (CLSI) subsequently will publish its first LA guideline. General agreement exists on issues such as sample preparation, the use of dilute Russell viper venom time (dRVVT) in diagnostic repertoires, the use of normalized ratios, calculations to demonstrate phospholipid dependence, calculations to demonstrate inhibition, and interpretive reporting. The ISTH recommendation to employ only dRVVT and activated partial thromboplastin time is not mirrored in the BCSH and CLSI documents. The potential for false negatives in mixing tests is acknowledged by all panels, yet they remain mandated by ISTH as there are occasions when they are crucial to diagnostic accuracy. BCSH indicates that a negative mixing test need not exclude the presence of a LA, and CLSI reprioritizes test order to screen-confirm-mix, the latter being considered unnecessary in specific circumstances. Opinions in the guidelines differ on setting cutoff levels (i.e., 97.5th vs. 99th percentile for normally distributed data). All guidelines cover testing of anticoagulated patients, more detail being given by BCSH and CLSI, who suggest that Taipan snake venom time is a useful adjunct test in patients receiving vitamin K antagonists. Although complete agreement is not apparent, the guidelines represent significant moves toward engendering common practices.

 
  • References

  • 1 Wong RCW, Favaloro EJ. A consensus approach to the formulation of guidelines for laboratory testing and reporting of antiphospholipid antibody assays. Semin Thromb Hemost 2008; 34 (04) 361-372
  • 2 Pengo V, Tripodi A, Reber G. , et al; Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost 2009; 7 (10) 1737-1740
  • 3 Keeling D, Mackie I, Moore GW, Greer IA, Greaves M. ; British Committee for Standards in Haematology. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol 2012; 157 (01) 47-58
  • 4 CLSI. Laboratory Testing for the Lupus Anticoagulant; Approved Guideline. CLSI document H60-A. Wayne, PA: Clinical and Laboratory Standards Institute; 2014
  • 5 Devreese K, Hoylaerts MF. Laboratory diagnosis of the antiphospholipid syndrome: a plethora of obstacles to overcome. Eur J Haematol 2009; 83 (01) 1-16
  • 6 Lippi G, Rossi R, Ippolito L. , et al. Influence of residual platelet count on routine coagulation, factor VIII and factor IX testing in post freeze-thaw samples. Semin Thromb Hemost 2013; 39 (07) 834-839
  • 7 Sletnes KE, Gravem K, Wisløff F. Preparation of plasma for the detection of lupus anticoagulants and antiphospholipid antibodies. Thromb Res 1992; 66 (01) 43-53
  • 8 Favaloro EJ. Preanalytical variables in coagulation testing. Blood Coagul Fibrinolysis 2007; 18 (01) 86-89
  • 9 Girón-González JA, García del Río E, Rodríguez C, Rodríguez-Martorell J, Serrano A. Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J Rheumatol 2004; 31 (08) 1560-1567
  • 10 de Groot PG, Lutters B, Derksen RH, Lisman T, Meijers JC, Rosendaal FR. Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. J Thromb Haemost 2005; 3 (09) 1993-1997
  • 11 Metjian A, Lim W. ASH evidence-based guidelines: should asymptomatic patients with antiphospholipid antibodies receive primary prophylaxis to prevent thrombosis?. Hematology (Am Soc Hematol Educ Program) 2009; 247-249
  • 12 Pengo V, Ruffatti A, Legnani C. , et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood 2011; 118 (17) 4714-4718
  • 13 Lawrie AS, Mackie IJ, Purdy G, Machin SJ. The sensitivity and specificity of commercial reagents for the detection of lupus anticoagulant show marked differences in performance between photo-optical and mechanical coagulometers. Thromb Haemost 1999; 81 (05) 758-762
  • 14 Gardiner C, Mackie IJ, Malia RG. , et al. The importance of locally derived reference ranges and standardized calculation of dilute Russell's viper venom time results in screening for lupus anticoagulant. Br J Haematol 2000; 111 (04) 1230-1235
  • 15 Miyakis S, Lockshin MD, Atsumi T. , et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4 (02) 295-306
  • 16 Gerbutavicius R, Fareed J, Messmore Jr HL. , et al. Reference intervals of the dilute tissue thromboplastin inhibition and dilute Russell's viper venom tests revisited. Clin Appl Thromb Hemost 2002; 8 (02) 115-124
  • 17 Kershaw G, Suresh S, Orellana D, Nguy YM. Laboratory identification of lupus anticoagulants. Semin Thromb Hemost 2012; 38 (04) 375-384
  • 18 CLSI. Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline—Third Edition. CLSI document EP28-A3c. Wayne, PA: Clinical and Laboratory Standards Institute; 2008
  • 19 Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995; 74 (04) 1185-1190
  • 20 Greaves M, Cohen H, Machin SJ, Mackie I. Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 2000; 109 (04) 704-715
  • 21 Jerrard-Dunne P, Evans A, McGovern R. , et al. Ethnic differences in markers of thrombophilia: implications for the investigation of ischemic stroke in multiethnic populations: the South London Ethnicity and Stroke Study. Stroke 2003; 34 (08) 1821-1826
  • 22 Tripodi A. Laboratory testing for lupus anticoagulants: a review of issues affecting results. Clin Chem 2007; 53 (09) 1629-1635
  • 23 McGlasson DL, Fritsma GA. Comparison of six dilute russell viper venom time lupus anticoagulant screen/confirm assay kits. Semin Thromb Hemost 2013; 39 (03) 315-319
  • 24 Blanco AN, Grand BE, Pieroni G, Peñalva LB, Voto LS, Lazzari MA. Behavior of diluted activated partial thromboplastin time in pregnant women with a lupus anticoagulant. Am J Clin Pathol 1993; 100 (02) 99-102
  • 25 Kumano O, Ieko M, Naito S, Yoshida M, Takahashi N. APTT reagent with ellagic acid as activator shows adequate lupus anticoagulant sensitivity in comparison to silica-based reagent. J Thromb Haemost 2012; 10: 2338-2343
  • 26 Moffat KA, Ledford-Kraemer MR, Plumhoff EA. , et al. Are laboratories following published recommendations for lupus anticoagulant testing? An international evaluation of practices. Thromb Haemost 2009; 101 (01) 178-184
  • 27 Jennings I, Kitchen S, Kitchen DP, Woods TA, Walker ID. ISTH/SSC lupus anticoagulant testing guidelines: how far have these been adopted by laboratories?. J Thromb Haemost 2011; 9 (10) 2117-2119
  • 28 Moore GW. Clinical utility of the less commonly employed assays for lupus anticoagulation detection: the evidence. J Coag Dis 2010; 2: 69-79
  • 29 Chantarangkul V, Tripodi A, Arbini A, Mannucci PM. Silica clotting time (SCT) as a screening and confirmatory test for detection of the lupus anticoagulants. Thromb Res 1992; 67 (04) 355-365
  • 30 Norbis F, Barbui T, Galli M. Diluted Russell's viper venom time and colloidal silica clotting time for the identification of the phospholipid-dependent inhibitors of coagulation. Thromb Res 1997; 85 (05) 427-431
  • 31 Jacobsen EM, Barna-Cler L, Taylor JM, Triplett DA, Wisløff F. The Lupus Ratio test—an interlaboratory study on the detection of Lupus anticoagulants by an APTT-based, integrated, and semi-quantitative test. Fifth International Survey of Lupus Anticoagulants—ISLA 5. Thromb Haemost 2000; 83 (05) 704-708
  • 32 Liestøl S, Jacobsen EM, Wisløff F. Dilute prothrombin time-based lupus ratio test. Integrated LA testing with recombinant tissue thromboplastin. Thromb Res 2002; 105 (02) 177-182
  • 33 Moore GW, Smith MP, Patel Y, Savidge GF. The Activated Seven Lupus Anticoagulant (ASLA) assay: a new test for lupus anticoagulants (LAs). Evidence that some LAs are detectable only in extrinsic pathway-based assays. Blood Coagul Fibrinolysis 2002; 13 (03) 261-269
  • 34 Mackie IJ, Lawrie AS, Greenfield RS, Guinto ER, Machin SJ. A new lupus anticoagulant test based on dilute prothrombin time. Thromb Res 2004; 114: 673-674 Abstract TH25
  • 35 Devreese KMJ. Evaluation of a new commercial dilute prothrombin time in the diagnosis of lupus anticoagulants. Thromb Res 2008; 123 (02) 404-411
  • 36 Jennings I, Mackie I, Arnout J, Preston FE. ; UK National External Quality Assessment Scheme for Blood Coagulation. Lupus anticoagulant testing using plasma spiked with monoclonal antibodies: performance in the UK NEQAS proficiency testing programme. J Thromb Haemost 2004; 2 (12) 2178-2184
  • 37 Lawrie AS, Mackie IJ, Purdy G, Greenfield RS, Guinto ER, Machin SJ. Lupus anticoagulant testing using a dilute prothrombin time with confirm procedure. J Thromb Haemost 2005; 3 (Suppl. 01) Abstract P1817
  • 38 Moore GW. Combining Taipan snake venom time/Ecarin time screening with the mixing studies of conventional assays increases detection rates of lupus anticoagulants in orally anticoagulated patients. Thromb J 2007; 5: 12
  • 39 de Groot PG, Urbanus RT. The future of antiphospholipid antibody testing. Semin Thromb Hemost 2012; 38 (04) 412-420
  • 40 Forastiero RR, Cerrato GS, Carreras LO. Evaluation of recently described tests for detection of the lupus anticoagulant. Thromb Haemost 1994; 72 (05) 728-733
  • 41 Moore GW, Smith MP, Savidge GF. The Ecarin time is an improved confirmatory test for the Taipan snake venom time in warfarinized patients with lupus anticoagulants. Blood Coagul Fibrinolysis 2003; 14 (03) 307-312
  • 42 Galli M, Borrelli G, Jacobsen EM. , et al. Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study. Blood 2007; 110 (04) 1178-1183
  • 43 Moore GW, Rangarajan S, Savidge GF. The activated seven lupus anticoagulant assay detects clinically significant antibodies. Clin Appl Thromb Hemost 2008; 14 (03) 332-337
  • 44 Male C, Lechner K, Speiser W, Pabinger I. Transient lupus anticoagulants in children: stepwise disappearance of diagnostic features. Thromb Haemost 2000; 83 (01) 174-175
  • 45 Thom J, Ivey L, Eikelboom J. Normal plasma mixing studies in the laboratory diagnosis of lupus anticoagulant. J Thromb Haemost 2003; 1 (12) 2689-2691
  • 46 Moore GW, Savidge GF. The dilution effect of equal volume mixing studies compromises confirmation of inhibition by lupus anticoagulants even when mixture specific reference ranges are applied. Thromb Res 2006; 118 (04) 523-528
  • 47 Arnout J. Antiphospholipid syndrome: diagnostic aspects of lupus anticoagulants. Thromb Haemost 2001; 86 (01) 83-91
  • 48 Favaloro EJ, Bonar R, Zebeljan D, Kershaw G, Marsden K. Laboratory investigation of lupus anticoagulants: mixing studies are sometimes required. J Thromb Haemost 2010; 8 (12) 2828-2831
  • 49 Reber G, Meijer P. In ECAT veritas?. Lupus 2012; 21 (07) 722-724
  • 50 Aboud M, Roddie C, Ward C, Coyle L. To mix with pooled normal plasma or not to mix: a comparative study of 2 approaches for assessing lupus anticoagulant inhibitory activity in the dilute Russell viper venom method. Clin Chem 2007; 53 (01) 143-145
  • 51 Devreese KMJ. No more mixing tests required for integrated assay systems in the laboratory diagnosis of lupus anticoagulants?. J Thromb Haemost 2010; 8 (05) 1120-1122
  • 52 Rosner E, Pauzner R, Lusky A, Modan M, Many A. Detection and quantitative evaluation of lupus circulating anticoagulant activity. Thromb Haemost 1987; 57 (02) 144-147
  • 53 Kershaw G, Orellana D. Mixing tests: diagnostic aides in the investigation of prolonged prothrombin times and activated partial thromboplastin times. Semin Thromb Hemost 2013; 39 (03) 283-290
  • 54 Kumano O, Ieko M, Naito S, Yoshida M, Takahashi N, Takashi A. Index of circulating anticoagulant cut-off value establishment in activated partial thromboplastin time mixing test for lupus anticoagulant diagnosis. J Thromb Haemost 2013; 11 (10) 1919-1922
  • 55 Moore GW, Brown KL, Bromidge ES, Drew AJ, Ledford-Kraemer MR. Lupus anticoagulant detection: out of control?. Int J Lab Hematol 2013; 35 (02) 128-136
  • 56 Machin SJ, Giddings JC, Greaves M. , et al. Guidelines on testing for the lupus anticoagulant. Lupus Anticoagulant Working Party on behalf of the BCSH Haemostasis and Thrombosis Task Force. J Clin Pathol 1991; 44 (11) 885-889
  • 57 Jennings I, Greaves M, Mackie IJ, Kitchen S, Woods TA, Preston FE. ; UK National External Quality Assessment Scheme for Blood Coagulation. Lupus anticoagulant testing: improvements in performance in a UK NEQAS proficiency testing exercise after dissemination of national guidelines on laboratory methods. Br J Haematol 2002; 119 (02) 364-369
  • 58 Dembitzer FR, Ledford Kraemer MR, Meijer P, Peerschke EI. Lupus anticoagulant testing: performance and practices by north american clinical laboratories. Am J Clin Pathol 2010; 134 (05) 764-773
  • 59 Cappucci G, Grandone E, Giuliani N, Margaglione M, Di Minno G. The use of frozen-thawed platelet-derived phospholipids as a confirmatory test for the diagnosis of lupus anticoagulants. Comparison with two commercial confirmatory system tests. Thromb Res 1999; 94 (06) 373-380
  • 60 Triplett DA, Barna LK, Unger GA. A hexagonal (II) phase phospholipid neutralization assay for lupus anticoagulant identification. Thromb Haemost 1993; 70 (05) 787-793
  • 61 Reber G, Roisin JP, Migaud M, de Moerloose P. Comparison of a platelet neutralization procedure with a hexagonal phase phospholipid neutralization assay as confirmatory tests for the presence of lupus anticoagulants. Thromb Res 1994; 73 (02) 131-135
  • 62 Tripodi A. To mix or not to mix in lupus anticoagulant testing? That is the question. Semin Thromb Hemost 2012; 38 (04) 385-389
  • 63 Hong SK, Hwang SM, Kim JE, Kim HK. Clinical significance of the mixing test in laboratory diagnoses of lupus anticoagulant: the fate of the mixing test in integrated lupus anticoagulant test systems. Blood Coagul Fibrinolysis 2012; 23 (08) 739-744
  • 64 Jacobsen EM, Wisløff F. False negative screening tests for lupus anticoagulants—an unrecognized problem?. Thromb Res 1996; 82 (05) 445-451
  • 65 Moore GW, Henley A, Greenwood CK, Rangarajan S. Further evidence of false negative screening for lupus anticoagulants. Thromb Res 2008; 121 (04) 477-484
  • 66 Tripodi A, Pengo V. More on: laboratory investigation of lupus anticoagulants: mixing studies are sometimes required. J Thromb Haemost 2011; 9 (10) 2126-2127
  • 67 Favaloro EJ, Bonar R, Marsden K. Internal quality control and external quality assurance in testing for antiphospholipid antibodies: part II—lupus anticoagulant. Semin Thromb Hemost 2012; 38 (04) 404-411
  • 68 Chantarangkul V, Biguzzi E, Asti D, Palmucci C, Tripodi A. Laboratory diagnostic outcome applying detection criteria recommended by the Scientific and Standardization Committee of the ISTH on Lupus Anticoagulant. Thromb Haemost 2013; 110 (01) 46-52
  • 69 Jouhikainen T. Detection of lupus anticoagulant by means of dilute Russell's viper venom time is affected by oral anticoagulant therapy. Blood Coagul Fibrinolysis 1990; 1 (06) 627-632
  • 70 Olteanu H, Downes KA, Patel J, Praprotnik D, Sarode R. Warfarin does not interfere with lupus anticoagulant detection by dilute Russell's viper venom time. Clin Lab 2009; 55 (3-4): 138-142
  • 71 Tripodi A, Chantarangkul V, Clerici M, Mannucci PM. Laboratory diagnosis of lupus anticoagulants for patients on oral anticoagulant treatment. Performance of dilute Russell viper venom test and silica clotting time in comparison with Staclot LA. Thromb Haemost 2002; 88 (04) 583-586
  • 72 Rooney AM, McNally T, Mackie IJ, Machin SJ. The Taipan snake venom time: a new test for lupus anticoagulant. J Clin Pathol 1994; 47 (06) 497-501
  • 73 Parmar K, Lefkou E, Doughty H, Connor P, Hunt BJ. The utility of the Taipan snake venom assay in assessing lupus anticoagulant status in individuals receiving or not receiving an oral vitamin K antagonist. Blood Coagul Fibrinolysis 2009; 20 (04) 271-275
  • 74 Halbmayer WM, Weigel G, Quehenberger P. , et al. Interference of the new oral anticoagulant dabigatran with frequently used coagulation tests. Clin Chem Lab Med 2012; 50 (09) 1601-1605
  • 75 Merriman E, Kaplan Z, Butler J, Malan E, Gan E, Tran H. Rivaroxaban and false positive lupus anticoagulant testing. Thromb Haemost 2011; 105 (02) 385-386
  • 76 van Os GM, de Laat B, Kamphuisen PW, Meijers JC, de Groot PG. Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time. J Thromb Haemost 2011; 9 (08) 1657-1659
  • 77 van Veen JJ, Smith J, Kitchen S, Makris M. Normal prothrombin time in the presence of therapeutic levels of rivaroxaban. Br J Haematol 2013; 160 (06) 859-861